Literature DB >> 32611650

Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study.

P G Conaghan1, Rieke Alten2, Atul Deodhar3, Emma Sullivan4,5, Stuart Blackburn5, Haijun Tian6, Kunal Gandhi6, Steffen M Jugl7, Vibeke Strand8,9.   

Abstract

BACKGROUND/
OBJECTIVE: The incidence of pain and/or fatigue in people with psoriatic arthritis (PsA) is associated with reduced health-related quality of life (HRQoL) and the ability to work, despite modern advanced therapeutic approaches. This real-world, international study examined these relationships in patients with PsA treated with tumour necrosis factor inhibitors (TNFi).
METHODS: Data from 13 countries were analysed. Patients with PsA and their physicians completed questionnaires capturing demographics, current therapy, current disease status, HRQoL and work status via Medical Outcomes Study 36-Item Short-Form version 2 (SF-36v2), 3-level 5-dimension EuroQoL questionnaire, Health Assessment Questionnaire Disability Index, and Work Productivity and Activity Impairment (WPAI) questionnaire.
RESULTS: 640 patients with PsA were included who had been receiving TNFi for ≥3 months and had completed SF-36v2 bodily pain and vitality domains. Of these, 33.1%, 29.2% and 37.7% of patients reported no, moderate and severe pain, respectively, and 31.9%, 22.5% and 45.6% of patients reported low, moderate and severe fatigue, respectively. Scores across HRQoL variables and WPAI were significantly different across pain and fatigue cohorts (all p<0.0001), with HRQoL and WPAI measures considerably worse in patients with moderate to severe pain or fatigue than those with low pain or fatigue.
CONCLUSIONS: Despite treatment with biologic agents such as TNFi, data from this global study demonstrated that substantial pain and/or fatigue persist in patients with PsA and that these are significantly associated with reduced HRQoL, physical function and work productivity. These findings suggest that there is an unmet need for additional PsA therapies. © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  Ankylosing Spondylitis; Anti-TNF; Corticosteroids; DAS28; DMARDs (biologic); Early Rheumatoid Arthritis; Knee Osteoarthritis; Osteoarthritis; Outcomes research; Patient perspective; Psoriatic Arthritis; Rheumatoid Arthritis; Treatment

Mesh:

Substances:

Year:  2020        PMID: 32611650      PMCID: PMC7425192          DOI: 10.1136/rmdopen-2020-001240

Source DB:  PubMed          Journal:  RMD Open        ISSN: 2056-5933


  36 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection.

Authors:  J E Ware; C D Sherbourne
Journal:  Med Care       Date:  1992-06       Impact factor: 2.983

3.  Work productivity loss and fatigue in psoriatic arthritis.

Authors:  Jessica A Walsh; Molly L McFadden; Michael D Morgan; Allen D Sawitzke; Kristina Callis Duffin; Gerald G Krueger; Daniel O Clegg
Journal:  J Rheumatol       Date:  2014-07-15       Impact factor: 4.666

4.  Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society.

Authors:  S Hukuda; M Minami; T Saito; H Mitsui; N Matsui; Y Komatsubara; H Makino; T Shibata; M Shingu; T Sakou; K Shichikawa
Journal:  J Rheumatol       Date:  2001-03       Impact factor: 4.666

5.  Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid.

Authors:  G Partsch; G Steiner; B F Leeb; A Dunky; H Bröll; J S Smolen
Journal:  J Rheumatol       Date:  1997-03       Impact factor: 4.666

6.  Patient perspective: reasons and methods for measuring fatigue in rheumatoid arthritis.

Authors:  John R Kirwan; Sarah Hewlett
Journal:  J Rheumatol       Date:  2007-05       Impact factor: 4.666

7.  Treatment Patterns Among Patients with Psoriatic Arthritis Treated with a Biologic in the United States: Descriptive Analyses from an Administrative Claims Database.

Authors:  Jessica A Walsh; Oluwakayode Adejoro; Benjamin Chastek; Jacqueline B Palmer; Peter Hur
Journal:  J Manag Care Spec Pharm       Date:  2018-03-20

8.  Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand.

Authors:  P Anderson; M Benford; N Harris; M Karavali; J Piercy
Journal:  Curr Med Res Opin       Date:  2008-10-02       Impact factor: 2.580

9.  The experience of pain and redness in patients with moderate to severe plaque psoriasis.

Authors:  Mona L Martin; Kenneth Gordon; Lionel Pinto; Donald M Bushnell; Dina Chau; Hema N Viswanathan
Journal:  J Dermatolog Treat       Date:  2015-09-04       Impact factor: 3.359

10.  Treatment patterns, unmet need, and impact on patient-reported outcomes of psoriatic arthritis in the United States and Europe.

Authors:  Alice Gottlieb; Jordi Gratacos; Ara Dikranian; Astrid van Tubergen; Lara Fallon; Birol Emir; Laraine Aikman; Timothy Smith; Linda Chen
Journal:  Rheumatol Int       Date:  2018-11-13       Impact factor: 2.631

View more
  6 in total

1.  Prevalence of pain and its association with quality of life of patients with heart failure in a developing country: findings from a multicenter cross-sectional study.

Authors:  Deema Mhesin; Hadeel Nazzal; Jalilah Amerah; Murad Azamtta; Yahia Ismail; Yunis Daralammouri; Mazen A Abdalla; Mohammad M Jaber; Amer A Koni; Sa'ed H Zyoud
Journal:  BMC Cardiovasc Disord       Date:  2022-09-28       Impact factor: 2.174

2.  Comparative performance of composite measures from two phase III clinical trials of ixekizumab in psoriatic arthritis.

Authors:  Laura C Coates; Josef S Smolen; Philip J Mease; M Elaine Husni; Joseph F Merola; Eric Lespessailles; Mitsumasa Kishimoto; Lisa Macpherson; Andrew J Bradley; Rebecca Bolce; Philip S Helliwell
Journal:  RMD Open       Date:  2022-09

Review 3.  Crosstalk between Interleukin-1β and Type I Interferons Signaling in Autoinflammatory Diseases.

Authors:  Philippe Georgel
Journal:  Cells       Date:  2021-05-08       Impact factor: 6.600

4.  Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.

Authors:  Proton Rahman; Philip J Mease; Philip S Helliwell; Atul Deodhar; Laure Gossec; Arthur Kavanaugh; Alexa P Kollmeier; Elizabeth C Hsia; Bei Zhou; Xiwu Lin; May Shawi; Chetan S Karyekar; Chenglong Han
Journal:  Arthritis Res Ther       Date:  2021-07-14       Impact factor: 5.156

5.  Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.

Authors:  Iain B McInnes; Laura M Sawyer; Kristen Markus; Corinne LeReun; Celia Sabry-Grant; Philip S Helliwell
Journal:  RMD Open       Date:  2022-03

6.  Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials.

Authors:  Iain B McInnes; Andrew J K Ostor; Philip J Mease; William Tillett; Xenofon Baraliakos; Kurt de Vlam; Louis Bessette; Ralph Lippe; Anna Maniccia; Dai Feng; Tianming Gao; Patrick Zueger; Christopher Saffore; Koji Kato; In-Ho Song; Atul Deodhar
Journal:  RMD Open       Date:  2022-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.